ALARIS Medical Increases Second Quarter Guidance.

Business Editors & Health/Medical Writers

ALARIS Medical Inc. (AMEX:AMI) said today that it anticipates that sales for the second quarter of 2002 should be about 10 percent higher than the second quarter a year ago.

This result would be at the high end of the previous guidance of 8 percent to 10 percent growth for the period. Included in the figure will be over $6 million in sales of the company's new MEDLEY(TM) Medication Safety System that continues to receive excellent responses from current and potential customers. As of June 30, 2002 an additional $3.5 million in MEDLEY(TM) System orders believed to be firm had been received.

Adjusted EBITDA should be above the previous guidance of a 12 percent to 15 percent increase over the second quarter of 2001. Growth of this indicator is now anticipated to be between 17 percent and 20 percent.

ALARIS Medical previously forecasted a "slightly positive net income" for the current quarter. It now appears that second quarter 2002 net income will slightly exceed the $854,000 that the company reported for the first quarter of 2002.

The company plans to release details on the second quarter results on Aug. 1, 2002. A conference call with portfolio managers and analysts will be available online at http://www.alarismed.com. The live Webcast will begin at 8:00 a.m. Pacific Time on Thursday, Aug. 1, 2002, with the replay beginning shortly after the completion of the live call. The replay of the conference call will also be accessible by telephone at 888/566-0411 (for domestic callers) and 402/998-0599 (for international callers), beginning shortly after the completion of the live call. Both the online and telephone replay will be available through August 15th.

ALARIS Medical Inc. (AMEX:AMI), through its wholly owned operating company, ALARIS Medical Systems Inc., develops practical solutions for medication safety at the point of care. The company designs, manufactures and markets intravenous (IV) medication delivery and infusion therapy devices, needle-free disposables and related monitoring equipment. ALARIS Medical's "smart" technology, tools and services reduce the risks and costs of medication errors, and safeguard patients and clinicians. The company provides its products, professional and technical support and training services to over 5,000 hospital and health care systems, as well as alternative care sites in more than 120 countries through its direct sales force and distributors. Headquartered in San Diego, ALARIS Medical employs approximately 2,600 people worldwide and operates manufacturing facilities in the United States, Mexico and the United Kingdom.

This news release contains forward-looking statements as defined in the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Persons reading this release are cautioned that such forward-looking statements involve risks and uncertainties, including the effect of legislative and regulatory changes affecting the health care industry, the potential of increased levels of competition, technological changes, the dependence of ALARIS Medical upon the success of new products (including its proprietary Guardrails(TM) Safety Software and the MEDLEY(TM) Medication Safety System) and ongoing research and development efforts including obtaining regulatory approvals, restrictions contained in the instruments governing the Company's indebtedness, and the significant leverage to which the Company is subject. Such risk factors are detailed in the Securities and Exchange Commission filings of ALARIS Medical, Inc. and ALARIS Medical Systems, Inc., including Forms 10-K for the year ended December 31, 2001, and other filings. The Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments.